COVID-19 Update: Vaccine notifications will go through MyScripps and email — please do not call your doctor. Learn more.

Continuous Glucose Monitoring Study

COVID-19 update:

In response to the COVID pandemic, Scripps Health has either temporarily suspended or limited enrollment with appropriate precautions for all clinical trials. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-18-7234
Athena Philis-Tsimikas, M.D.
The MOBILE study looks to see how blood sugar is managed when using a Continuous Glucose Monitor (CGM) compared to fingerstick testing in people with Type 2 Diabetes taking long-acting insulin once or twice a day.

Inclusion Criteria

  • Be 30 years old or older.
  • Have been taking long-acting insulin for the last 6 months.
  • Have stable medications for the last 3 months.
  • Have a smartphone that works with the devices used in the study (smartphone compatibility will be assessed).
  • Have diabetes managed by a primary care physician (PCP), NP, PA, etc.

Exclusion Criteria

  • Have diabetes managed by an endocrinologist.

Additional Info

  • A CGM measures the glucose level in the fluid under the skin. It consists of a sensor which is inserted into the skin, a transmitter attached to the sensor and a display device. Every 5 minutes, the transmitter sends glucose readings to the display device.

Contact Info:

  • Isabel Garcia, RN
  • garcia.maria6@scrippshealth.org
  • 858-309-2602